ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 242

The Effectiveness of Medications for Fibromyalgia Based on Patient Experiences

Robert Katz1, Jessica Polyak Wokurka 2 and Ben Small 2, 1Rush University Medical Center, Chicago, IL, 2Rheumatology Associates, Chicago, IL

Meeting: 2019 ACR/ARP Annual Meeting

Keywords: fibromyalgia, medical, medication and education

  • Tweet
  • Email
  • Print
Session Information

Date: Sunday, November 10, 2019

Title: Fibromyalgia & Other Clinical Pain Syndromes Poster

Session Type: Poster Session (Sunday)

Session Time: 9:00AM-11:00AM

Background/Purpose: To assess patients’ global assessment of frequently used treatments for the fibromyalgia syndrome (FMS), we asked patients with fibromyalgia to rank medications they have tried for their effectiveness.

Methods: 95 patients (mean age of 50.5) diagnosed with fibromyalgia based on the 2011 ACR criteria, 88 females and 7 males, completed an in-office questionnaire regarding the effectiveness of various medications often used to treat fibromyalgia. The study ranked 9 medications, which include Pregablin, Gabapentin, Duloxetine, Muscle Relaxants, Sleep Aids, Stimulants, ADHD Medications, Opiate Pain Medications, and NSAIDS. Patients rated the medications using this scale:  1=minimally helpful, 2=somewhat helpful, 3=moderately helpful, 4=very helpful. 

Results: The three medications that were most positively rated by patients were opiate pain meds (mean=2.8), medications to improve sleep (mean= 2.8), and ADHD stimulants for fibro fog symptoms (mean=2.6).

The medications with the lowest effectiveness ratings by fibromyalgia patients included: gabapentin (mean=0.73); duloxetine (mean=1.02); pregabalin (mean=1.26). 59.1% of FMS patients reported little or no help from pregabalin, and 83.3 % found gabapentin to be little help.   

Conclusion: Fibromyalgia patients rated the effectiveness of various medications that they tried. Pain medication, sleep aids and stimulants given for the attention deficit component of fibro fog were judged by patients to be the most helpful.


Disclosure: R. Katz, None; J. Polyak Wokurka, None; B. Small, None.

To cite this abstract in AMA style:

Katz R, Polyak Wokurka J, Small B. The Effectiveness of Medications for Fibromyalgia Based on Patient Experiences [abstract]. Arthritis Rheumatol. 2019; 71 (suppl 10). https://acrabstracts.org/abstract/the-effectiveness-of-medications-for-fibromyalgia-based-on-patient-experiences-4/. Accessed .
  • Tweet
  • Email
  • Print

« Back to 2019 ACR/ARP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/the-effectiveness-of-medications-for-fibromyalgia-based-on-patient-experiences-4/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology